United Therapeutics CEO Martine Rothblatt Sold About $8.4M Through a December Exercise Window

ROTHBLATT MARTINE A sold roughly $9.0M of UTHR stock across the latest visible selling window. The pattern matters because it happened after the market already had a clear narrative about the company, not while investors were still trying to guess whether the business was working.

What Happened

Date	Code	Shares	Price	Estimated Value
2025-12-19	S	1,500	$507.61	$761,418
2025-12-19	S	500	$505.45	$252,725
2025-12-18	S	1,500	$510.86	$766,295
2025-12-18	S	500	$509.42	$254,708
2025-12-18	S	2,000	$507.24	$1.0M
2025-12-17	S	2,500	$501.35	$1.3M
2025-12-17	S	1,500	$500.52	$750,780
2025-12-16	S	500	$497.17	$248,585

The visible cluster added up to about 18,000 shares at an average sale price near $500.36. That is big enough to matter, but it is still much more useful as a pattern read than as a one-day headline.

Why It Matters

United Therapeutics remained one of biotech's more unusual stories heading into year-end 2025: a profitable rare-disease company with both commercial cash flow and long-duration optionality around organ manufacturing. That combination matters because Rothblatt was selling after the stock had already spent much of the year in premium-territory valuation rather than while the business was under obvious stress.

That does not make the selling automatically bearish. It does mean investors should distinguish between healthy founder or executive liquidity and a broader change in alignment. That distinction usually becomes clearer when you compare the cadence, size, and remaining ownership after the window closes.

What Investors Should Not Overstate

This is not a story about management walking away. The better read is that the insider used a visible liquidity window while still leaving substantial ownership on the table. That makes the important question forward-looking: does the pattern repeat, accelerate, or stop?

For readers trying to separate routine selling from a deeper signal, the right comparison set is not just the insider's own history. It is also what peers like Alnylam, Vertex, Biogen, BioMarin are doing and how those stocks are trading around their own earnings cycles.

Key Facts

Insider	ROTHBLATT MARTINE A
Company	UNITED THERAPEUTICS Corp
Recent sell window	2025-12-15 to 2025-12-19
Estimated value	$9.0M
Average sale price	$500.36

What to Watch

• UTHR commercial durability: whether Tyvaso-family execution keeps justifying the premium biotechnology multiple.
• Exercise cadence: whether the December cluster stays a contained option event or repeats in 2026.
• Ownership floor: whether Rothblatt maintains a visibly aligned stake after the sales.
• Pipeline optionality: whether longer-duration organ-manufacturing projects keep supporting investor patience.
• Peer comparison: whether Alnylam, Vertex, and Biogen trade with a similar risk-reward mix.